Transform treatment for immune-mediated diseases, empower people to reimagine their lives.
About Alumis
We are advancing a late-stage portfolio of next-generation targeted therapies to optimize patient outcomes across a wide range of immune-mediated diseases.
PIPELINE
Our precision approach builds on integrated scientific insights – powered by our proprietary data analytics platform – to drive smarter therapeutic development.
science
We foster a culture where teams elevate, challenge, and nurture each other, living our values while driving our mission forward.
careers
September 1, 2026 Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
August 13, 2026 Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
August 10, 2026 Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
More News
